About E3 ubiquitin-protein ligase FANCL
E3 ubiquitin-protein ligase FANCL (FANCL) is a protein
from Homo sapiens identified by UniProt accession
Q9NW38, 375 residues long.
MolForge cross-references it against 0 known binders and
348 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase FANCL |
| UniProt accession | Q9NW38 |
| Gene | FANCL |
| Organism | Homo sapiens |
| Length | 375 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (348)
Diseases linked to this target (Open Targets).
- Fanconi anemia complementation group L · score 0.79
- Fanconi anemia · score 0.78
- myelodysplastic syndrome · score 0.46
- acute myeloid leukemia · score 0.46
- Fanconi anemia complementation group A · score 0.45
- BMI-adjusted waist circumference · score 0.40
- BMI-adjusted waist-hip ratio · score 0.39
- neurodegenerative disease · score 0.37
- head and neck malignant neoplasia · score 0.37
- Abnormal radial ray morphology · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NW38-F1 | alphafold | PREDICTED | 91.34 | — |
Amino-acid sequence (375 residues)
MAVTEASLLR QCPLLLPQNR SKTVYEGFIS AQGRDFHLRI VLPEDLQLKN ARLLCSWQLR TILSGYHRIV QQRMQHSPDL MSFMMELKML LEVALKNRQE LYALPPPPQF YSSLIEEIGT LGWDKLVYAD TCFSTIKLKA EDASGREHLI TLKLKAKYPA ESPDYFVDFP VPFCASWTPQ SSLISIYSQF LAAIESLKAF WDVMDEIDEK TWVLEPEKPP RSATARRIAL GNNVSINIEV DPRHPTMLPE CFFLGADHVV KPLGIKLSRN IHLWDPENSV LQNLKDVLEI DFPARAILEK SDFTMDCGIC YAYQLDGTIP DQVCDNSQCG QPFHQICLYE WLRGLLTSRQ SFNIIFGECP YCSKPITLKM SGRKH
Explore E3 ubiquitin-protein ligase FANCL with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets